FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	urden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* STAHL NEIL (Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD					2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [REGN] 3. Date of Earliest Transaction (Month/Day/Year) 12/09/2020										(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) EVP Research and Development					
(Street) TARRY			10591 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)										Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Nor	n-Deriv	vativ	e Se	curities	s Ac	qui	ired, [Disp	osed o	f, or E	enet	ficially	y Owned					
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		,	3. Transaction Code (Instr.							es ally Following	6. Ownership Form: Direct (D) or Indirec (I) (Instr. 4)	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								Ī	Code	v	Amount	(A (D	or	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)		
Common Stock				02/2	02/26/2020				\top	G	V	750		D	\$0.0	20,	979		D		
Common	Stock			12/0	9/202	20			\top	A ⁽¹⁾		1,688	8	A	\$0.0	24,	715	D			
Common Stock																5,766			Ι .	By 401(k) Plan	
Common	Stock															9,1	134	I by 2019 GRAT			
		-	Γable II -									sed of, onvertil				Owned				<u> </u>	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	d Date,	4. Transa Code (8)	ction	5. Number of		6. D	Date Exe piration onth/Day	rcisa Date	able and	7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		mount	8. Price of Derivative Security (Instr. 5)		es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Dat Exe	te ercisable		xpiration ate	Title	or Nu of	nount imber iares						
Non- Qualified Stock Option (right to	\$492	12/09/2020			A		17,500			(2)	1	2/09/2030	Commo Stock	ⁱⁿ 17	7,500	\$0.0	17,50	0	D		

Explanation of Responses:

- 1. Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 9, 2022 and 50% on December 9, 2024.
- 2. The stock option award vests in four equal annual installments, commencing one year after the date of grant.

/s/**Neil Stahl

12/10/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).